October 7, 2024

Jarrett Boon
Chief Executive Officer
Safety Shot, Inc.
1061 E. Indiantown Rd., Ste. 110
Jupiter, FL 33477

        Re: Safety Shot, Inc.
            Registration Statement on Form S-3
            Filed September 24, 2024
            File No. 333-282315
Dear Jarrett Boon:

       We have conducted a limited review of your registration statement and
have the
following comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3
Prospectus Summary, page 3

1.     We note your disclosure on page 4 that "research studies will be carried
out
       addressing dose, ingredient selection and efficacy across multiple
indications to help
       bolster product development and product offerings." Please revise to
briefly discuss
       these future research studies.
2.     We note your disclosure on page 4 that you "have conducted extensive
research and
       experimentation involving a substantial number of volunteers under the
influence of
       alcohol" and that you "have recently completed [y]our clinical trials of
the Safety Shot
       Dietary Supplement which have shown a statistically significant
reduction in the BAC
       of the participants." Please revise to discuss these studies and
clinical trials in further
       detail. In particular, please disclose the date(s) and location(s) of
the studies and trials,
       the sponsor(s), the number of participants, including how participants
were selected,
 October 7, 2024
Page 2

       the results of the studies and trials, including how results were
measured, key
       assumptions, any serious adverse events, and whether statistical
significance was
       demonstrated, including supporting p-values, as appropriate. Please also
disclose
       whether any of the parties involved, including the sponsors in the
studies and/or trials,
       are affiliates or partners of Safety Shot.
3.     We note your statement on page 6: "As of the date hereof, the Company
owns five
       patents, including the patent (US 9,186,350 B2) and patent (US
10,028,991 B2) for
       the composition of the Safety Shot Dietary Supplement used for
minimizing the
       harmful effects associated with alcohol consumption by supporting the
metabolism of
       alcohol." Please revise to disclose the specific products, product
groups and
       technologies to which such patents relate, whether the patents are owned
or licensed,
       the type of patent protection, expiration dates for such patents on an
individual basis
       and the jurisdiction covered by each patent.
Incorporation Of Certain Information By Reference, page 18

4.     Please revise to incorporate by reference all of the current reports on
Form 8-K
       required pursuant to Item 12(a)(2) of Form S-3.
General

5.     Please revise your disclosures to clearly discuss the securities being
registered for
       resale on this registration statement, including the 1,098,029
previously issued shares
       of common stock and the 800,000 shares of common stock issuable upon the
exercise
       of common stock purchase warrants. In particular, please discuss the
transactions
       pursuant to which these securities were issued, and file the applicable
transaction
       documents as exhibits to this registration statement. We note your
disclosure on page
       9 that common stock was issued to Todd Gibson pursuant to a securities
purchase
       agreement dated September 20, 2024, your disclosure on page 12 that
common stock
       options were issued to Wall and Broad Capital pursuant to a stock option
agreement
       dated September 6, 2024, and your disclosures on page 13 that you
entered into loan
       agreements on April 20, 2022 with Greentree and L&H pursuant to which
you sold
       warrants, and that on January 19, 2023, you entered into a PIPE
agreement with
       certain purchasers.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
 October 7, 2024
Page 3

       Please contact Juan Grana at 202-551-6034 or Margaret Sawicki at
202-551-7153
with any other questions.



                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Industrial
Applications and
                                                        Services
cc:   Arthur S. Marcus, Esq.